Because of the anti-inflammatory properties of thymoquinone (TQ), as the main bioactive substance of Nigella sativa L., this systematic review aimed at assessing the therapeutic effects of N. sativa ...and its main bioactive substance in the management of patients with osteoarthritis (OA) based on the in vivo, in vitro, and in clinical studies. The methodology was adjusted based on the Cochrane Handbook recommendations. All published articles focusing on N. sativa as a therapeutic agent for the treatment of OA or its animal model were searched up to 20 April 2022 in PubMed, Medline, Web of Sciences, and Scopus databases. The search process was carried out using the following keywords: "Nigella sativa", "Black seed', "Black cumin", and "Thymoquinone" in combination with "Osteoarthritis". Finally, 14 articles remained, including five intervention clinical trial, two human studies, and seven animal studies. Four of five intervention studies showed that N. sativa administration led to relief in pain intensity. In the other clinical trial, no difference was reported between the N. sativa and control groups in terms of pain relief among OA patients. Studies demonstrated the anti-inflammatory and chondroprotective effects of TQ as the main bioactive substance of N. sativa. The evidence confirmed the anti-inflammatory and chondroprotective effects of N. sativa in the management of OA patients. Considering the lack of significant adverse effects such as allergic reaction to N. sativa in the aforementioned studies, this substance can be recommended as a safe adjuvant treatment to relieve OA pain, compared to nonsteroidal anti-inflammatory drugs and other analgesics.
Because of the anti-inflammatory properties of thymoquinone (TQ), as the main bioactive substance of Nigella sativa, this systematic review aimed at assessing the therapeutic effects of N. sativa and ...its main bioactive substance in the management of patients with osteoarthritis (OA) in vivo, in vitro, and in clinical studies. The methodology was adjusted based on the Cochrane Handbook recommendations. All published articles focusing on N. sativa as a therapeutic agent for the treatment of OA or its animal model were searched up to 20 April 2022 in PubMed, Medline, Web of Sciences, and Scopus databases. The search process was carried out using the following keywords: "Nigella sativa", "Black seed', "Black cumin", and "Thymoquinone" in combination with "Osteoarthritis". Finally, 14 articles remained, including five intervention clinical trial, two human in vivo studies, and seven animal studies. Four of five intervention studies showed that N. sativa administration led to relief in pain intensity. In the other clinical trial, no difference was reported between the N. sativa and control groups in terms of pain relief among OA patients. Studies demonstrated the anti-inflammatory and chondroprotective effects of TQ as the main bioactive substance of NS. The evidence confirmed the anti-inflammatory and chondroprotective effects of N. sativa in the management of OA patients. Due to the lack of allergic reaction to N. sativa in the aforementioned studies, this substance can be used as a safe adjuvant treatment to relieve OA pain, compared to nonsteroidal anti-inflammatory drugs and other analgesics.
L'ankylose de l'articulation temporo-mandibulaire (ATM) est définie comme une constriction permanente des mâchoires avec ouverture buccale inférieure à 30mm mesurée entre les incisives, survenant en ...raison d'une fusion osseuse, fibreuse ou fibro-osseuse. L'arthrose est une cause rare de l'ankylose de L'ATM. Nous rapportons un cas d'ankylose de l'ATM d'origine arthrosique, afin de préciser les particularités diagnostiques et thérapeutiques de cette entité pathologique assez rare.
It is impossible to achieve a diagnosis without a comprehensive list of possible diagnostic explanations for a certain symptom or syndrome. Joint complaints are very frequent in general practice, ...paediatrics, emergency medicine and naturally rheumatology and orthopaedics. The differential diagnosis of joint and surrounding tissue pain and inflammation is impressively challenging. Orthopaedic surgeons and rheumatologists deal with different aspects of this subject, while primary care physicians need to have a wider perspective that includes both orthopaedic and rheumatic disorders. The purpose of this paper is to provide a unified, comprehensive, clear and concise guide to this subject that will include both orthopaedic and rheumatic disorders and may serve the practitioner as basic reference for differential diagnosis. Short dictionary-style definitions would be given for each disorder in order to provide a 'bird's-eye view', rather than an in-depth description of many diseases. Medical students, residents and primary care physicians are the primary target audience, but we believe that even the experienced orthopaedic surgeon or rheumatologist may benefit from a systematic and well-organised method.
Background:
This study aimed to assess the responsiveness of the Trapeziometacarpal Arthrosis Symptoms and Disability (TASD) questionnaire after corticosteroid injections and operative management for ...trapeziometacarpal osteoarthritis (TMC-OA).
Methods:
This longitudinal cohort study included patients with TMC-OA who underwent treatment (corticosteroid injection or surgery). Measurements occurred at baseline and follow-up time points: 6 weeks, 3 months, 6 months, and 1 year. Patient measures were collected electronically using a data repository platform. The TASD is a validated psychometric patient-administered scale. We examined responsiveness by correlating the TASD scores with another known effective indicator of change (shortened Disabilities of the Arm, Shoulder, and Hand QuickDASH). Repeated score measurements over time were analyzed using analysis of variance, and correlations between questionnaires were reported with repeated measures correlation and Pearson correlation coefficients.
Results:
The nonsurgical cohort undergoing corticosteroid injections included 31 (66%) women and 16 (34%) men, and the surgical cohort included 29 (71%) women and 12 (29%) men. Both the QuickDASH and the TASD captured a statistically significant improvement in symptom burden postoperatively (P < .0001 for both questionnaires), whereas no statistical significance was noted after corticosteroid injections (P = .45 and P = .34, respectively). There was a strong correlation between QuickDASH and TASD questionnaires (r = 0.87, P < .0001).
Conclusions:
The TASD is a promising TMC-OA–specific questionnaire to capture responsiveness following treatment, particularly following surgery. The responsiveness of TASD was demonstrated in the TMC-OA cohort. Further research is needed to define a minimal clinically important difference.
Trapeziometacarpal (TMC) joint prosthesis poses its own challenges for the treatment of TMC arthrosis, especially when compared with the present gold standard, arthroplasty. The aim of this study was ...to highlight possible outcome differences and patients’ satisfaction regarding the treatment of TMC arthrosis.
We evaluated 100 patients with TMC arthrosis treated in two centers and divided into two groups: group A received TMC prosthesis (Touch), whereas group B was treated with arthroplasty, with a 2-year follow-up period.
In a comparative analysis, findings revealed group A's superiority in the shortened disabilities of the arm, shoulder and hand questionnaire scores at 1 and 6 months, with significant differences: 34.6% vs 67.1% and 2% vs 9.1%, respectively (P < .0001). Although group A also showed lower the shortened disabilities of the arm, shoulder and hand questionnaire scores at 3 months, this was not statistically significant. Notably, at 1 and 2 years, group A demonstrated better scores without statistical significance. The Kapandji score differed significantly at 6 months: 9.8 vs 9.1 (P = .029). Although the visual analog scale showed generally lower values for the prosthesis group, no statistical differences emerged. Additionally, the M1/M2 ratio became significant postoperatively, favoring group A (P < .05).
Trapeziometacarpal prosthesis shows promise for TMC arthrosis, enhancing function, thumb length, and patient recovery, warranting further research and x-ray guidance.
Therapeutic III.
PDF
